Gene therapy clinical trials worldwide to 2017: An update
暂无分享,去创建一个
I. Alexander | Anais K. Amaya | S. L. Ginn | Michael L. Edelstein | Mohammad R. Abedi | Samantha L Ginn | Anais K Amaya | Ian E Alexander | Michael Edelstein | Mohammad R Abedi | M. Abedi | Michael Edelstein
[1] Michel Sadelain. CAR therapy: the CD19 paradigm. , 2015, The Journal of clinical investigation.
[2] Matthew J. Moscou,et al. A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.
[3] J. Bennett. Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] M. Gonçalves,et al. Engineered Viruses as Genome Editing Devices , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Steven M. Weisberg,et al. A CRISPR New World: Attitudes in the Public toward Innovations in Human Genetic Modification , 2017, Front. Public Health.
[6] R. J. Ramamurthi,et al. Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[7] Daniele Merico,et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism , 2017, Nature Medicine.
[8] S. Russell,et al. Oncolytic Virotherapy: A Contest between Apples and Oranges. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Alexander Meissner,et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.
[10] P. Ortinski,et al. Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing , 2017, Molecular therapy. Methods & clinical development.
[11] B. Smart. Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome , 2011, Pediatrics.
[12] John K. Hall,et al. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. , 2016, Human molecular genetics.
[13] L. Notarangelo,et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.
[14] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[15] N. Sardesai,et al. Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy , 2017, Clinical Cancer Research.
[16] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[17] Jens Boch,et al. Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.
[18] C. von Kalle,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.
[19] A. Miccio,et al. Gene Therapy for β-Hemoglobinopathies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] S. Ludwig,et al. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy , 2017, Biological chemistry.
[21] T. Flotte,et al. Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency , 2017 .
[22] E. Bender. Gene therapy: Industrial strength , 2016, Nature.
[23] Dennis Normile. iPS cell therapy reported safe. , 2017, Science.
[24] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[25] W. Baehr,et al. RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations , 2014, Front. Mol. Neurosci..
[26] David Cyranoski,et al. CRISPR gene-editing tested in a person for the first time , 2016, Nature.
[27] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[28] Shinya Yamanaka,et al. Induced pluripotent stem cell technology: a decade of progress , 2016, Nature Reviews Drug Discovery.
[29] A. Sood,et al. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. , 2016, Cancer treatment reviews.
[30] J. Couzin. Method to Silence Genes Earns Loud Praise , 2006, Science.
[31] E. Callaway. Doubts raised about CRISPR gene-editing study in human embryos , 2017 .
[32] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Inder M. Verma,et al. Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.
[34] Wenbo Zhou,et al. Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells , 2009, Stem cells.
[35] Ying Sun,et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.
[36] J. Grieger,et al. Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.
[37] J. Chamberlain,et al. Progress toward Gene Therapy for Duchenne Muscular Dystrophy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] Brian K. Kaspar,et al. Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[39] H. Ertl,et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. , 2013, Blood.
[40] K. Mansfield,et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.
[41] Michael Rothe,et al. Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity , 2014, Science Translational Medicine.
[42] Yong Huang,et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.
[43] Luigi Naldini,et al. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.
[44] Adrian J. Thrasher,et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.
[45] K. Cornetta,et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.
[46] R. Stewart,et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.
[47] Michael Recht,et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.
[48] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[49] Jianhui Gong,et al. Correction of a pathogenic gene mutation in human embryos , 2018, Yearbook of Paediatric Endocrinology.
[50] S. Ylä-Herttuala. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] Sara Reardon,et al. Chinese scientists genetically modify human embryos , 2015, Nature.
[52] Anirvan Ghosh,et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes , 2017, Nature Biotechnology.
[53] Sara Reardon,et al. Leukaemia success heralds wave of gene-editing therapies , 2015, Nature.
[54] N. Svrzikapa,et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.
[55] M. Boulton,et al. Systemic Injection of RPE65-Programmed Bone Marrow-Derived Cells Prevents Progression of Chronic Retinal Degeneration , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[56] A. Biffi. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] R. Grossman,et al. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.
[58] J. Davies,et al. Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.
[59] V. Ricotti,et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.
[60] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[61] S Chandrasegaran,et al. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[62] Yong Wang,et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9 , 2017, Science.
[63] Xiuyan Wang,et al. Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.
[64] M. Nirenberg. Will society be prepared? , 1967, Science.
[65] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[66] Jean Bennett,et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.
[67] Lei Zhang,et al. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. , 2002, Biochimica et biophysica acta.
[68] J. Couzin. Nobel Prize in Physiology or Medicine. Method to silence genes earns loud praise. , 2006, Science.
[69] Michael Dallas,et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.
[70] Pratima Chowdary,et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.
[71] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[72] Patrick Hong,et al. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing , 2016, Molecular therapy. Methods & clinical development.
[73] Xiuli Wang,et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.
[74] F. Demichelis,et al. Hit and go CAS9 delivered through a lentiviral based self-limiting circuit , 2017, Nature Communications.
[75] F. Bushman,et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. , 2017, Blood.
[76] Kathryn L. Parsley,et al. Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.
[77] R. Calne,et al. Gene therapy for hemophilia A. , 2006, Discovery medicine.
[78] Ian J Constable,et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial , 2015, The Lancet.
[79] Manfred Schmidt,et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.
[80] Jo Wixon,et al. Gene therapy clinical trials worldwide to 2007—an update , 2007, The journal of gene medicine.
[81] A. Krieg,et al. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.
[82] J. Wixon,et al. Gene therapy clinical trials worldwide 1989–2004—an overview , 2004, The journal of gene medicine.
[83] Nick Tyler,et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[84] Helen E Heslop,et al. CAR-T Cell Therapy for Lymphoma. , 2016, Annual review of medicine.
[85] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[86] Michel Sadelain,et al. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[87] Y. Doyon,et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.
[88] E. Wagner,et al. Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). , 2015, Chemical reviews.
[89] Roland W Herzog,et al. Evading the immune response upon in vivo gene therapy with viral vectors. , 2009, Current opinion in molecular therapeutics.
[90] S. Hughes,et al. Altering the Genome by Homologous Recombination , 2010 .
[91] J. Rasko,et al. Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant , 2017, The New England journal of medicine.
[92] J. Bourke,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.
[93] Irene Georgakoudi,et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles , 2016, Proceedings of the National Academy of Sciences.
[94] K. Makino,et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product , 1987, Journal of bacteriology.
[95] Sara Reardon,et al. Japan stem-cell trial stirs envy , 2014, Nature.
[96] K. Lundstrom. Special Issue: Gene Therapy with Emphasis on RNA Interference , 2015, Viruses.
[97] Frederic D Bushman,et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.
[98] D J Segal,et al. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[99] S. Borwornpinyo,et al. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene , 2016, Human gene therapy.
[100] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[101] Jo Wixon,et al. Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.
[102] David A. Williams,et al. Evolving Gene Therapy in Primary Immunodeficiency. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[103] David A. Williams,et al. Hematopoietic Stem‐Cell Gene Therapy for Cerebral Adrenoleukodystrophy , 2017, The New England journal of medicine.
[104] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[105] Evelina Mazzolari,et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.
[106] Robert Lanza,et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.
[107] P. Rosenfeld,et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies , 2015, The Lancet.
[108] Kathryn L. Parsley,et al. Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.
[109] S. Orkin,et al. Paying for future success in gene therapy , 2016, Science.
[110] A. Higuchi,et al. Stem Cell Therapies for Reversing Vision Loss. , 2017, Trends in biotechnology.
[111] Xianquan Zhang,et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[112] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[113] P. Cullis,et al. Lipid Nanoparticle Systems for Enabling Gene Therapies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[114] M. Roncarolo,et al. Ten years of gene therapy for primary immune deficiencies. , 2009, Hematology. American Society of Hematology. Education Program.
[115] Kathleen A. Marshall,et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.
[116] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[117] Giovanni Staurenghi,et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. , 2017, The New England journal of medicine.
[118] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[119] Hao Yin,et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.
[120] I. Constable,et al. Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration , 2016, EBioMedicine.
[121] Claudio Mussolino,et al. Refining strategies to translate genome editing to the clinic , 2017, Nature Medicine.
[122] Seppo Ylä-Herttuala,et al. Cardiovascular Gene Therapy: Past, Present, and Future. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[123] E. Lanphier,et al. Don’t edit the human germ line , 2015, Nature.
[124] K. G. Rajeev,et al. Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.
[125] Michael L Kaufman,et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[126] K. Flanigan,et al. Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene , 2014, Molecular therapy. Nucleic acids.
[127] K. Garber. RIKEN suspends first clinical trial involving induced pluripotent stem cells , 2015, Nature Biotechnology.
[128] Kathleen A. Marshall,et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.
[129] T. Flotte,et al. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[130] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[131] A. Aartsma-Rus. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. , 2017, Nucleic acid therapeutics.
[132] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[133] Jennifer A. Doudna,et al. A prudent path forward for genomic engineering and germline gene modification , 2015, Science.
[134] Daniel G. Anderson,et al. Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.
[135] Monya Baker,et al. Gene-editing nucleases , 2011, Nature Methods.
[136] D. Russell,et al. Human gene targeting by viral vectors , 1998, Nature Genetics.
[137] L. Naldini,et al. Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products , 2017, EMBO molecular medicine.
[138] M. Weitzman,et al. Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.
[139] S. Cole,et al. Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .
[140] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[141] X. Anguela,et al. Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a , 2017 .
[142] Philippe Horvath,et al. A decade of discovery: CRISPR functions and applications , 2017, Nature Microbiology.
[143] Sara Reardon. Gene-editing record smashed in pigs , 2015, Nature.
[144] Kyung-Chul Choi,et al. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy , 2016, Oncotarget.
[145] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[146] Steve Cunningham,et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .
[147] I. Alexander,et al. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects , 2017, Journal of Inherited Metabolic Disease.
[148] Frederic D. Bushman,et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.
[149] Henry Klassen,et al. Stem cells in clinical trials for treatment of retinal degeneration , 2016, Expert opinion on biological therapy.
[150] I. Graham,et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.